Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation

Hasegawa D, Sato R, Prasitlumkum N, Nishida K, Keaton B, Acquah SO, Im Lee Y (2022) · ASAIO Journal · n=0

RCT evidence detailTrial reference

GRADE LowCohort / case seriesCondition: Venous Congestion in Surgical Flaps →

Study Profile

Design: systematic review and random-effects meta-analysis of 11 observational studies (Embase, Cochrane Central, MEDLINE)
Sample size (n): 0
Intervention: Bivalirudin anticoagulation in ECMO patients
Comparator: Heparin anticoagulation in ECMO patients
Primary endpoint: Short-term mortality
Primary result: Bivalirudin associated with significantly lower short-term mortality (OR 0.71, 95% CI 0.55-0.92, p=0.01, I²=7%) compared with heparin in ECMO patients
Follow-up duration: Hospital discharge / short-term
PMID: 36194483

Key Findings

Mortality signal in favor of bivalirudin (OR 0.71, p=0.01)
Low heterogeneity (I²=7%) supports robustness
Adds quantitative mortality endpoint to ECMO anticoagulant literature
Random-effects model used to account for clinical heterogeneity
Calls for prospective RCT confirmation

Limitations

All included studies observational
Selection bias - bivalirudin often reserved for HIT or bleeding patients
Variable anticoagulation monitoring strategies across studies
Cannot establish causation
Not applicable to whole-leech hirudotherapy

Clinical Implications

Hasegawa 2022 contributes a positive mortality signal to the broader bivalirudin ECMO evidence base. For ASH, the meta-analysis demonstrates how the synthetic thrombin inhibitor pathway generates emerging mortality signals under retrospective synthesis, structurally separate from the K040187 device-leech US clinical practice. The mortality finding warrants RCT confirmation.

Related Trials

Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation

McMichael A, Weller J, Li X, Hatton L, Zia A, Raman L (2024)

Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support

Trigonis R, Smith N, Porter S, Anderson E, Jennings M, Kapoor R, Hage C, Moiz S, Garcia J, Rahman O (2021)

Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation

Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022)

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review

Valdes CA, Sharaf OM, Bleiweis MS, Jacobs JP, Mumtaz M, Sharaf RM, Jeng EI, Peek GJ (2023)

← Back to RCT Library